You are not logged in!
Do you want to login? It's free!
Who do you implu? Create a Free Account!
Related News Outlets
- Case Studies in Environmental Medicine | ATSDR - CSEM
- CDC Clinician Outreach and Communication Activity (COCA)
- CDC Emergency Preparedness and Response: Recent Outbreaks and Incidents
- CDC Emergency Preparedness and Response: What's New
- CDC Emergency Text Messages
- CDC en Español
- CDC Flu updates
- CDC HIV/AIDS Prevention
- CDC Travel Notices plus News and Announcments
- CDC's Morbidity and Mortality Weekly Report
- CDC's Preventing Chronic Disease
- CDRH Consumer News
- Centers for Disease Control and Prevention
- Environmental Health
- FDA Consumer Health Information Updates
- FDA MedWatch
- Food and Drug Administration Press Releases
- Food and Drug Administration--Enforcement Report
- Food and Drug Adminstration (FDA): CDRHNew
- Food and Drug Adminstration (FDA): Patient Safety News
- Health Marketing Musings
- HHS News and Events
- National Environmental Public Health Tracking Program
- Public Health Matters
- What's New at CBER
A new study shows that Kineret (anakinra), a medication approved for the treatment of rheumatoid arthritis, is effective in stopping the progression of organ damage in people with neonatal-onset multisystem inflammatory disease (NOMID). This rare and debilitating genetic disorder causes persistent inflammation and ongoing tissue damage. The research was performed by scientists at the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), part of the National Institutes of Health.
Create a free account and automatically get e-mail alerts on news like this!